down arrow

ResMed, Inc.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US7611521078
USD
251.51
0.07 (0.03%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

250.63252.61

52 Week

199.92293.81
Valuation
Technical
Day's Volume

CASH

161.98 k

Shareholding (Mar 2025)

FII

19.78%

Held by 395 FIIs

DII

49.69%

Held by 44 DIIs

Promoter

0.01%

How big is ResMed, Inc.?

22-Jun-2025

As of Jun 18, ResMed, Inc. has a market capitalization of $47.13 billion, with net sales of $5.02 billion and a net profit of $1.31 billion reported over the latest four quarters.

Market Cap: As of Jun 18, ResMed, Inc. has a market capitalization of 47,132.87 million, categorizing it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, ResMed, Inc. reported net sales of 5,021.53 million and a net profit of 1,313.26 million.<BR><BR>Balance Sheet Snapshot: As of Jun 24, the company reported shareholder's funds of 4,864.04 million and total assets of 6,872.39 million.

Read More

What does ResMed, Inc. do?

22-Jun-2025

ResMed, Inc. develops and manufactures medical devices and software for respiratory disorders, with recent net sales of $1.29 billion and a market cap of $47.13 billion. Key metrics include a P/E ratio of 36.00 and a dividend yield of 2.65%.

Overview: <BR>ResMed, Inc. is a holding company engaged in the development, manufacturing, distribution, and marketing of medical devices and cloud-based software applications for diagnosing, treating, and managing respiratory disorders, operating within the Pharmaceuticals & Biotechnology industry and classified as a Large Cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1,292 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 365 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 47,132.87 Million (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 36.00 <BR>Dividend Yield: 2.65% <BR>Debt Equity: -0.04 <BR>Return on Equity: 23.58% <BR>Price to Book: 8.50<BR><BR>Contact Details: <BR>Address: 9001 Spectrum Center Blvd, SAN DIEGO CA: 92123-1438 <BR>Tel: 1 858 7462400 <BR>Website: https://www.resmed.com/

Read More

Who are in the management team of ResMed, Inc.?

22-Jun-2025

As of March 2022, the management team of ResMed, Inc. includes Dr. Peter Farrell (Non-Executive Chairman), Mr. Michael Farrell (CEO and Director), Mr. Ronald Taylor (Lead Independent Director), and Independent Directors Ms. Carol Burt, Mr. Jan De Witte, and Ms. Karen Drexler. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of ResMed, Inc. includes the following individuals:<BR><BR>- Dr. Peter Farrell, who serves as the Non-Executive Chairman of the Board.<BR>- Mr. Michael Farrell, who is the Chief Executive Officer and a Director.<BR>- Mr. Ronald Taylor, who holds the position of Lead Independent Director.<BR>- Ms. Carol Burt, who is an Independent Director.<BR>- Mr. Jan De Witte, who is also an Independent Director.<BR>- Ms. Karen Drexler, who serves as an Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Read More

Is ResMed, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, ResMed, Inc. is considered an attractive investment due to its undervaluation indicated by a P/E ratio of 36, a PEG ratio of 1.15, and a strong ROCE of 30.33%, despite recent underperformance against the S&P 500, as it has achieved a year-to-date return of 17.23%.

As of 17 October 2025, the valuation grade for ResMed, Inc. has moved from fair to attractive, indicating a more favorable assessment of its market position. The company appears to be undervalued, supported by a P/E ratio of 36, a PEG ratio of 1.15, and a robust ROCE of 30.33%. In comparison to peers, ResMed's P/E ratio is slightly higher than Edwards Lifesciences Corp. at 31.17 and Agilent Technologies, Inc. at 27.42, but lower than DexCom, Inc. at 53.65, suggesting a competitive valuation within its industry.<BR><BR>Despite recent underperformance against the S&P 500 over the past week and month, where it returned -1.44% and -1.33% respectively, ResMed has shown resilience with a year-to-date return of 17.23%, outperforming the index's 13.30%. This performance, combined with its attractive valuation metrics, reinforces the view that ResMed is positioned favorably in the market.

Read More

Is ResMed, Inc. technically bullish or bearish?

28-Oct-2025

As of October 24, 2025, ResMed, Inc. shows a neutral technical trend with mixed signals, underperforming the S&P 500 recently, and suggesting a cautious investment approach.

As of 24 October 2025, the technical trend for ResMed, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across different time frames. The weekly MACD and KST are both mildly bearish, while the monthly MACD remains bullish. The weekly Bollinger Bands indicate a bearish trend, contrasted by a mildly bullish monthly perspective. Daily moving averages show a mildly bullish stance. <BR><BR>In terms of performance, ResMed has underperformed the S&P 500 over the past week and month, with returns of -3.21% and -5.36% compared to the S&P's gains of 1.92% and 2.32%, respectively. However, year-to-date, ResMed is slightly behind the S&P 500, with a return of 13.47% versus 15.47%. Overall, the mixed indicators suggest a cautious approach.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Management Efficiency with a high ROCE of 25.79%

 
2

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.50 times

 
3

Healthy long term growth as Operating profit has grown by an annual rate 15.84%

 
4

The company has declared Positive results for the last 5 consecutive quarters

5

With ROCE of 30.33%, it has a attractive valuation with a 8.90 Enterprise value to Capital Employed

6

Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks

 
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 52,609 Million (Mid Cap)

stock-summary
P/E

36.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.45%

stock-summary
Debt Equity

-0.09

stock-summary
Return on Equity

23.36%

stock-summary
Price to Book

8.82

Revenue and Profits:
Net Sales:
1,348 Million
(Quarterly Results - Jun 2025)
Net Profit:
380 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.14%
0%
-8.14%
6 Months
0.63%
0%
0.63%
1 Year
2.31%
0%
2.31%
2 Years
55.7%
0%
55.7%
3 Years
7.99%
0%
7.99%
4 Years
-1.28%
0%
-1.28%
5 Years
19.94%
0%
19.94%

ResMed, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
ResMed, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics

ResMed, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics

ResMed, Inc. has experienced notable stock price fluctuations, currently priced at $259.21 after a previous close of $265.26. The company has shown mixed technical indicators, with varying trends across different time frames. Its performance has lagged behind the S&P 500 in both short-term and longer-term returns.

Read More

Is ResMed, Inc. technically bullish or bearish?

As of 24 October 2025, the technical trend for ResMed, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across different time frames. The weekly MACD and KST are both mildly bearish, while the monthly MACD remains bullish. The weekly Bollinger Bands indicate a bearish trend, contrasted by a mildly bullish monthly perspective. Daily moving averages show a mildly bullish stance. In terms of performance, ResMed has underperformed the S&P 500 over the past week and month, with returns of -3.21% and -5.36% compared to the S&P's gains of 1.92% and 2.32%, respectively. However, year-to-date, ResMed is slightly behind the S&P 500, with a return of 13.47% versus 15.47%. Overall, the mixed indicators suggest a cautious approach....

Read More

Is ResMed, Inc. technically bullish or bearish?

As of 24 October 2025, the technical trend for ResMed, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed signals across different time frames. The weekly MACD and KST are mildly bearish, while the monthly MACD is bullish. The Bollinger Bands indicate a bearish trend on the weekly chart but mildly bullish on the monthly. Daily moving averages are mildly bullish, suggesting some short-term strength. Overall, the stock has underperformed the S&P 500 over the past week and month, with returns of -3.21% and -5.36% compared to the S&P's 1.92% and 2.32%, respectively....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
11.72%
EBIT Growth (5y)
15.84%
EBIT to Interest (avg)
41.25
Debt to EBITDA (avg)
0.50
Net Debt to Equity (avg)
-0.04
Sales to Capital Employed (avg)
0.79
Tax Ratio
16.74%
Dividend Payout Ratio
22.30%
Pledged Shares
0
Institutional Holding
71.73%
ROCE (avg)
25.79%
ROE (avg)
21.53%
Valuation key factors
Factor
Value
P/E Ratio
36
Industry P/E
Price to Book Value
8.57
EV to EBIT
29.34
EV to EBITDA
25.87
EV to Capital Employed
8.90
EV to Sales
9.42
PEG Ratio
1.15
Dividend Yield
2.62%
ROCE (Latest)
30.33%
ROE (Latest)
23.58%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 154 Schemes (30.51%)

Foreign Institutions

Held by 395 Foreign Institutions (19.78%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 10.20% vs 9.01% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 29.95% vs 27.21% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,348.00",
          "val2": "1,223.20",
          "chgp": "10.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "530.90",
          "val2": "436.00",
          "chgp": "21.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "9.60",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.90",
          "val2": "0.70",
          "chgp": "171.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "379.70",
          "val2": "292.20",
          "chgp": "29.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "338.70%",
          "val2": "311.70%",
          "chgp": "2.70%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2025 is 9.84% vs 10.95% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2025 is 37.19% vs 13.75% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,146.30",
          "val2": "4,685.30",
          "chgp": "9.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,923.20",
          "val2": "1,600.30",
          "chgp": "20.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "12.60",
          "val2": "60.10",
          "chgp": "-79.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "7.60",
          "val2": "-54.00",
          "chgp": "114.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,400.70",
          "val2": "1,021.00",
          "chgp": "37.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "327.90%",
          "val2": "295.40%",
          "chgp": "3.25%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
1,348.00
1,223.20
10.20%
Operating Profit (PBDIT) excl Other Income
530.90
436.00
21.77%
Interest
0.00
9.60
-100.00%
Exceptional Items
1.90
0.70
171.43%
Consolidate Net Profit
379.70
292.20
29.95%
Operating Profit Margin (Excl OI)
338.70%
311.70%
2.70%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 10.20% vs 9.01% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 29.95% vs 27.21% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Jun'25stock-summary
Jun'25
Jun'24
Change(%)
Net Sales
5,146.30
4,685.30
9.84%
Operating Profit (PBDIT) excl Other Income
1,923.20
1,600.30
20.18%
Interest
12.60
60.10
-79.03%
Exceptional Items
7.60
-54.00
114.07%
Consolidate Net Profit
1,400.70
1,021.00
37.19%
Operating Profit Margin (Excl OI)
327.90%
295.40%
3.25%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Jun 2025 is 9.84% vs 10.95% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jun 2025 is 37.19% vs 13.75% in Jun 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About ResMed, Inc. stock-summary
stock-summary
ResMed, Inc.
Pharmaceuticals & Biotechnology
ResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases. The Company operates through two segments: Sleep and Respiratory Care segment, and the Software-as-a-Service (SaaS) segment. SDB includes obstructive sleep apnea (OSA) and other respiratory disorders that occur during sleep. Its cloud-based software digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company's portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, portable oxygen concentrators (POCs) and cloud-based software informatics solutions.
Company Coordinates stock-summary
Company Details
9001 Spectrum Center Blvd , SAN DIEGO CA : 92123-1438
stock-summary
Tel: 1 858 7462400
stock-summary
https://www.resmed.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."